HIV / AIDS - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 916
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H8B4453DEC1EN
Leaflet:

Download PDF Leaflet

HIV/AIDS - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, HIV/AIDS - Pipeline Review, H2 2015’, provides an overview of the HIV/AIDS’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for HIV/AIDS, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV/AIDS and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of HIV/AIDS
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for HIV/AIDS and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the HIV/AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the HIV/AIDS pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for HIV/AIDS
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding HIV/AIDS pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
HIV / AIDS Overview
Therapeutics Development
HIV / AIDS - Therapeutics under Development by Companies
HIV / AIDS - Therapeutics under Investigation by Universities/Institutes
HIV / AIDS - Pipeline Products Glance
HIV / AIDS - Products under Development by Companies
HIV / AIDS - Products under Investigation by Universities/Institutes
HIV / AIDS - Companies Involved in Therapeutics Development
HIV / AIDS - Therapeutics Assessment
Drug Profiles
HIV / AIDS - Recent Pipeline Updates
HIV / AIDS - Dormant Projects
HIV / AIDS - Discontinued Products
HIV / AIDS - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for HIV / AIDS, H2 2015
Number of Products under Development for HIV / AIDS - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..9)
HIV / AIDS - Pipeline by Abivax S.A., H2 2015
HIV / AIDS - Pipeline by Adaptimmune Limited, H2 2015
HIV / AIDS - Pipeline by AiCuris GmbH & Co. KG, H2 2015
HIV / AIDS - Pipeline by Akshaya Bio Inc., H2 2015
HIV / AIDS - Pipeline by Altor BioScience Corporation, H2 2015
HIV / AIDS - Pipeline by AltraVax Inc., H2 2015
HIV / AIDS - Pipeline by Amarna Therapeutics B.V., H2 2015
HIV / AIDS - Pipeline by American Gene Technologies International Inc., H2 2015
HIV / AIDS - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2015
HIV / AIDS - Pipeline by Antigen Express, Inc., H2 2015
HIV / AIDS - Pipeline by Aphios Corporation, H2 2015
HIV / AIDS - Pipeline by Apotex, Inc., H2 2015
HIV / AIDS - Pipeline by Argos Therapeutics, Inc., H2 2015
HIV / AIDS - Pipeline by Arno Therapeutics, Inc., H2 2015
HIV / AIDS - Pipeline by Avexa Limited, H2 2015
HIV / AIDS - Pipeline by BCI Pharma, H2 2015
HIV / AIDS - Pipeline by Beth Israel Deaconess Medical Center, Inc., H2 2015
HIV / AIDS - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2015
HIV / AIDS - Pipeline by Bionor Pharma ASA, H2 2015
HIV / AIDS - Pipeline by Biosantech SA, H2 2015
HIV / AIDS - Pipeline by BioSource Pharm, Inc., H2 2015
HIV / AIDS - Pipeline by Biotron Limited, H2 2015
HIV / AIDS - Pipeline by Boehringer Ingelheim GmbH, H2 2015
HIV / AIDS - Pipeline by Bristol-Myers Squibb Company, H2 2015
HIV / AIDS - Pipeline by C4X Discovery Limited, H2 2015
HIV / AIDS - Pipeline by Calimmune, Inc., H2 2015
HIV / AIDS - Pipeline by Celldex Therapeutics, Inc., H2 2015
HIV / AIDS - Pipeline by Chipscreen Biosciences Ltd, H2 2015
HIV / AIDS - Pipeline by Cocrystal Pharma, Inc., H2 2015
HIV / AIDS - Pipeline by CompleGen, Inc., H2 2015
HIV / AIDS - Pipeline by Critical Outcome Technologies Inc., H2 2015
HIV / AIDS - Pipeline by CureVac GmbH, H2 2015
HIV / AIDS - Pipeline by Cytodyn Inc., H2 2015
HIV / AIDS - Pipeline by DNAVEC Corporation, H2 2015
HIV / AIDS - Pipeline by Dong-A ST Co., Ltd., H2 2015
HIV / AIDS - Pipeline by Enzo Biochem, Inc., H2 2015
HIV / AIDS - Pipeline by EpiVax, Inc., H2 2015
HIV / AIDS - Pipeline by Etubics Corporation, H2 2015
HIV / AIDS - Pipeline by Evofem, Inc., H2 2015
HIV / AIDS - Pipeline by FIT Biotech Oy, H2 2015
HIV / AIDS - Pipeline by Formune S.L., H2 2015
HIV / AIDS - Pipeline by Fountain Biopharma Inc., H2 2015
HIV / AIDS - Pipeline by Frontier Biotechnologies Co., Ltd, H2 2015
HIV / AIDS - Pipeline by GeneCure LLC, H2 2015
HIV / AIDS - Pipeline by Genetic Immunity, Inc, H2 2015
HIV / AIDS - Pipeline by Genticel S.A., H2 2015
HIV / AIDS - Pipeline by GeoVax Labs, Inc., H2 2015
HIV / AIDS - Pipeline by Gilead Sciences, Inc., H2 2015
HIV / AIDS - Pipeline by GlaxoSmithKline Plc, H2 2015
HIV / AIDS - Pipeline by Globeimmune, Inc., H2 2015
HIV / AIDS - Pipeline by H-Phar S.A., H2 2015
HIV / AIDS - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015
HIV / AIDS - Pipeline by Heat Biologics, Inc., H2 2015
HIV / AIDS - Pipeline by Heptares Therapeutics Limited, H2 2015
HIV / AIDS - Pipeline by Humabs BioMed SA, H2 2015
HIV / AIDS - Pipeline by iCo Therapeutics Inc., H2 2015
HIV / AIDS - Pipeline by Immune Response BioPharma, Inc., H2 2015
HIV / AIDS - Pipeline by Immunocore Limited, H2 2015
HIV / AIDS - Pipeline by Immunomic Therapeutics, Inc., H2 2015
HIV / AIDS - Pipeline by Immuron Limited, H2 2015
HIV / AIDS - Pipeline by ImQuest Life Sciences, H2 2015
HIV / AIDS - Pipeline by InnaVirVax SA, H2 2015
HIV / AIDS - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
HIV / AIDS - Pipeline by Japan Tobacco Inc., H2 2015
HIV / AIDS - Pipeline by Johnson & Johnson, H2 2015
HIV / AIDS - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
HIV / AIDS - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
HIV / AIDS - Pipeline by Kineta, Inc., H2 2015
HIV / AIDS - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015
HIV / AIDS - Pipeline by Longevity Biotech, Inc, H2 2015
HIV / AIDS - Pipeline by MacroGenics, Inc., H2 2015
HIV / AIDS - Pipeline by Medestea Research & Production S.p.A., H2 2015
HIV / AIDS - Pipeline by Medivir AB, H2 2015
HIV / AIDS - Pipeline by Merck & Co., Inc., H2 2015
HIV / AIDS - Pipeline by Mologen AG, H2 2015
HIV / AIDS - Pipeline by Mymetics Corporation, H2 2015
HIV / AIDS - Pipeline by Myrexis, Inc., H2 2015

LIST OF FIGURES

Number of Products under Development for HIV / AIDS, H2 2015
Number of Products under Development for HIV / AIDS - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Abivax S.A.
Adaptimmune Limited
AiCuris GmbH & Co. KG
Akshaya Bio Inc.
Altor BioScience Corporation
AltraVax Inc.
Amarna Therapeutics B.V.
American Gene Technologies International Inc.
Amplyx Pharmaceuticals, Inc.
Antigen Express, Inc.
Aphios Corporation
Apotex, Inc.
Argos Therapeutics, Inc.
Arno Therapeutics, Inc.
Avexa Limited
BCI Pharma
Beth Israel Deaconess Medical Center, Inc.
BioClonetics Immunotherapeutics, Inc.
Bionor Pharma ASA
Biosantech SA
BioSource Pharm, Inc.
Biotron Limited
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
C4X Discovery Limited
Calimmune, Inc.
Celldex Therapeutics, Inc.
Chipscreen Biosciences Ltd
Cocrystal Pharma, Inc.
CompleGen, Inc.
Critical Outcome Technologies Inc.
CureVac GmbH
Cytodyn Inc.
DNAVEC Corporation
Dong-A ST Co., Ltd.
Enzo Biochem, Inc.
EpiVax, Inc.
Etubics Corporation
Evofem, Inc.
FIT Biotech Oy
Formune S.L.
Fountain Biopharma Inc.
Frontier Biotechnologies Co., Ltd
GeneCure LLC
Genetic Immunity, Inc
Genticel S.A.
GeoVax Labs, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Globeimmune, Inc.
H-Phar S.A.
Hadasit Medical Research Services & Development Ltd
Heat Biologics, Inc.
Heptares Therapeutics Limited
Humabs BioMed SA
iCo Therapeutics Inc.
Immune Response BioPharma, Inc.
Immunocore Limited
Immunomic Therapeutics, Inc.
Immuron Limited
ImQuest Life Sciences
InnaVirVax SA
Inovio Pharmaceuticals, Inc.
Japan Tobacco Inc.
Johnson & Johnson
KAEL-GemVax Co., Ltd.
Karyopharm Therapeutics, Inc.
Kineta, Inc.
Laboratorios Del Dr. Esteve S.A.
Longevity Biotech, Inc
MacroGenics, Inc.
Medestea Research & Production S.p.A.
Medivir AB
Merck & Co., Inc.
Mologen AG
Mymetics Corporation
Myrexis, Inc.
NanoBio Corporation
NanoViricides, Inc.
Navigen Pharmaceuticals, Inc.
NeED Pharma s.r.l.
Nektar Therapeutics
New World Laboratories, Inc.
Novartis AG
Omeros Corporation
Oncolys BioPharma Inc.
OncoNOx ApS
Oncovir, Inc.
Orbis Biosciences, Inc.
Osel Inc.
OyaGen Inc.
PaxVax, Inc.
Pepscan Therapeutics
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharis Biotec GmbH
Pharmsynthez
Phoenix Biotechnology, Inc.
Polymun Scientific Immunbiologische Forschung GmbH
Presidio Pharmaceuticals, Inc.
Profectus BioSciences, Inc.
RAPID Pharmaceuticals AG
ReceptoPharm, Inc.
Rodos BioTarget GmbH
Rottapharm SpA
Sangamo BioSciences, Inc.
Sanofi
Sanofi Pasteur SA
Savoy Pharmaceuticals, Inc.
SEEK Group
Sequoia Pharmaceuticals, Inc.
Serometrix, LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
SKAU Vaccines ApS
Spider Biotech
Starpharma Holdings Limited
Susavion Biosciences, Inc.
Taiga Biotechnologies, Inc.
TaiMed Biologics Inc.
Takara Bio Inc.
TAmiRNA GmbH
TechnoVax, Inc.
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries Limited
TGV-Laboratories
Theraclone Sciences, Inc.
Theravectys SA
Tobira Therapeutics, Inc.
Transgene Biotek Limited
TVAX Biomedical, Inc.
United Biomedical, Inc.
United Therapeutics Corporation
Vaccibody AS
VG Life Sciences, Inc.
Vichem Chemie Research Ltd.
ViiV Healthcare Limited
Viriom Ltd.
ViroLogik GmbH
ViroXis Corporation
Skip to top


HIV/AIDS Testing: Market Research Report US$ 4,950.00 Jan, 2015 · 306 pages

Ask Your Question

HIV / AIDS - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: